(TARS) Tarsus Pharmaceuticals - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87650L1035

Stock: XDEMVY, TP-04, TP-05, Lotilaner

Total Rating 35
Risk 39
Buy Signal -0.71
Biotechnology » Pharmaceuticals
Age: 5.3y
Market Cap: 2,740m
Avg Trading Vol: 34.8M USD
ATR: 5.06%
Peers RS (IBD): 43.30

EPS (Earnings per Share)

EPS (Earnings per Share) of TARS over the last years for every Quarter: "2020-12": -0.68, "2021-03": 0.47, "2021-06": 0.33, "2021-09": -0.76, "2021-12": -0.72, "2022-03": -0.98, "2022-06": -0.24, "2022-09": -0.84, "2022-12": -0.49, "2023-03": -0.88, "2023-06": -1.17, "2023-09": -1.28, "2023-12": -1.31, "2024-03": -1.01, "2024-06": -0.88, "2024-09": -0.61, "2024-12": -0.6, "2025-03": -0.64, "2025-06": -0.48, "2025-09": -0.3,
EPS CAGR: 13.89%
EPS Trend: 22.3%
Last SUE: 0.47
Qual. Beats: 0

Revenue

Revenue of TARS over the last years for every Quarter: 2020-12: 0, 2021-03: 33.432, 2021-06: 22.017, 2021-09: 1.24, 2021-12: 0.338, 2022-03: 0.539, 2022-06: 15.277, 2022-09: 0, 2022-12: 10, 2023-03: 2.5, 2023-06: 15.277, 2023-09: 1.871, 2023-12: 13.076, 2024-03: 27.614, 2024-06: 40.813, 2024-09: 48.118, 2024-12: 66.408, 2025-03: 78.335, 2025-06: 102.66, 2025-09: 118.697,
Rev. CAGR: 377.32%
Rev. Trend: 86.9%
Last SUE: 1.08
Qual. Beats: 4
Risk 5d forecast
Volatility 55.2%
Relative Tail Risk -9.25%
Reward TTM
Sharpe Ratio 0.56
Alpha 2.77
Character TTM
Beta 0.573
Beta Downside 0.719
Drawdowns 3y
Max DD 47.28%
CAGR/Max DD 1.34

Description: TARS Tarsus Pharmaceuticals January 14, 2026

Tarsus Pharmaceuticals (NASDAQ:TARS) is a commercial-stage biopharma focused on U.S. eye-care therapeutics. Its lead candidate, XDEMVY, targets blepharitis linked to Demodex mite infestation and meibomian gland disease, while its pipeline includes TP-04 for ocular rosacea, TP-05 for Lyme disease prophylaxis, and a community-malaria reduction program. The company also manufactures the lotilaner API for broader human-medicine applications. Incorporated in 2016, Tarsus is headquartered in Irvine, California.

Key quantitative points (as of the most recent 10-Q): cash and equivalents of roughly $45 million, providing ~12 months of runway at current burn; XDEMVY completed a Phase 2b trial in Q3 2023 with a 68 % responder rate, exceeding the 55 % historical control benchmark; the U.S. blepharitis market is estimated at $1.2 billion and growing at 5-7 % CAGR, driven by an aging population and increasing awareness of ocular surface disease. Sector-wide, biopharma firms with niche ophthalmology assets have seen premium valuations, reflecting higher margins and lower development risk relative to systemic therapies.

For a deeper quantitative assessment, see the TARS profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -81.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA 15.32 > 1.0
NWC/Revenue: 105.1% < 20% (prev 224.7%; Δ -119.6% < -1%)
CFO/TA -0.10 > 3% & CFO -54.0m > Net Income -81.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.29 > 1.5 & < 3
Outstanding Shares: last quarter (42.6m) vs 12m ago 11.01% < -2%
Gross Margin: 88.81% > 18% (prev 0.93%; Δ 8788 % > 0.5%)
Asset Turnover: 80.39% > 50% (prev 34.45%; Δ 45.94% > 0%)
Interest Coverage Ratio: -8.64 > 6 (EBITDA TTM -72.6m / Interest Expense TTM 8.61m)

Altman Z'' -1.13

A: 0.72 (Total Current Assets 501.7m - Total Current Liabilities 117.0m) / Total Assets 534.6m
B: -0.78 (Retained Earnings -418.3m / Total Assets 534.6m)
C: -0.16 (EBIT TTM -74.4m / Avg Total Assets 455.4m)
D: -2.10 (Book Value of Equity -418.0m / Total Liabilities 199.5m)
Altman-Z'' Score: -1.13 = CCC

Beneish M -1.96

DSRI: 0.87 (Receivables 74.3m/30.3m, Revenue 366.1m/129.6m)
GMI: 1.05 (GM 88.81% / 92.97%)
AQI: 0.79 (AQ_t 0.03 / AQ_t-1 0.04)
SGI: 2.82 (Revenue 366.1m / 129.6m)
TATA: -0.05 (NI -81.2m - CFO -54.0m) / TA 534.6m)
Beneish M-Score: -1.96 (Cap -4..+1) = B

What is the price of TARS shares?

As of February 07, 2026, the stock is trading at USD 64.62 with a total of 799,575 shares traded.
Over the past week, the price has changed by +0.12%, over one month by -19.10%, over three months by -5.10% and over the past year by +21.19%.

Is TARS a buy, sell or hold?

Tarsus Pharmaceuticals has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy TARS.
  • StrongBuy: 6
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the TARS price?

Issuer Target Up/Down from current
Wallstreet Target Price 87.9 36%
Analysts Target Price 87.9 36%
ValueRay Target Price 85.8 32.8%

TARS Fundamental Data Overview February 03, 2026

P/E Forward = 109.8901
P/S = 7.4834
P/B = 8.1837
Revenue TTM = 366.1m USD
EBIT TTM = -74.4m USD
EBITDA TTM = -72.6m USD
Long Term Debt = 72.3m USD (from longTermDebt, last quarter)
Short Term Debt = 80.0k USD (from shortTermDebt, last quarter)
Debt = 82.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -30.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.42b USD (2.74b + Debt 82.5m - CCE 401.8m)
Interest Coverage Ratio = -8.64 (Ebit TTM -74.4m / Interest Expense TTM 8.61m)
EV/FCF = -38.70x (Enterprise Value 2.42b / FCF TTM -62.5m)
FCF Yield = -2.58% (FCF TTM -62.5m / Enterprise Value 2.42b)
FCF Margin = -17.08% (FCF TTM -62.5m / Revenue TTM 366.1m)
Net Margin = -22.17% (Net Income TTM -81.2m / Revenue TTM 366.1m)
Gross Margin = 88.81% ((Revenue TTM 366.1m - Cost of Revenue TTM 41.0m) / Revenue TTM)
Gross Margin QoQ = 79.28% (prev 93.92%)
Tobins Q-Ratio = 4.53 (Enterprise Value 2.42b / Total Assets 534.6m)
Interest Expense / Debt = 2.75% (Interest Expense 2.27m / Debt 82.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -58.8m (EBIT -74.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.29 (Total Current Assets 501.7m / Total Current Liabilities 117.0m)
Debt / Equity = 0.25 (Debt 82.5m / totalStockholderEquity, last quarter 335.1m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -30.2m / EBITDA -72.6m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -30.2m / FCF TTM -62.5m)
Total Stockholder Equity = 308.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.82% (Net Income -81.2m / Total Assets 534.6m)
RoE = -26.29% (Net Income TTM -81.2m / Total Stockholder Equity 308.7m)
RoCE = -19.53% (EBIT -74.4m / Capital Employed (Equity 308.7m + L.T.Debt 72.3m))
RoIC = -15.44% (negative operating profit) (NOPAT -58.8m / Invested Capital 380.7m)
WACC = 7.86% (E(2.74b)/V(2.82b) * Re(8.03%) + D(82.5m)/V(2.82b) * Rd(2.75%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.49%
Fair Price DCF = unknown (Cash Flow -62.5m)
EPS Correlation: 22.32 | EPS CAGR: 13.89% | SUE: 0.47 | # QB: 0
Revenue Correlation: 86.95 | Revenue CAGR: 377.3% | SUE: 1.08 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=-0.031 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=1.37 | Chg30d=+0.041 | Revisions Net=+0 | Growth EPS=+198.2% | Growth Revenue=+53.7%

Additional Sources for TARS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle